Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large cell lymphoma in children, adolescents and adult patients: results of the French AcSe-crizotinib trial

The French phase II AcSé-crizotinib trial aimed to evaluate the safety and efficacy of crizotinib in patients with ALK, ROS1 and MET-driven malignancies including ALK-positive, anaplastic large cell lymphoma (ALK+ALCL). ALK+ALCL patients 12 months or older with measurable disease and no standard car...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2023-09, Vol.191, p.112984-112984, Article 112984
Hauptverfasser:	Brugières, L, Cozic, N, Houot, R, Rigaud, C, Sibon, D, Arfi-Rouche, J, Bories, P, Cottereau, AS, Delmer, A, Ducassou, S, Garnier, N, Lamant, L, Leruste, A, Millot, F, Moalla, S, Morschhauser, F, Nolla, M, Pagnier, A, Reguerre, Y, Renaud, L, Schmitt, A, Simonin, M, Verschuur, A, Hoog Labouret, N, Mahier Ait Oukhatar, C, Vassal, G
Format:	Artikel
Sprache:	eng
Schlagworte:	ALK inhibitors anaplastic large cell lymphoma ALK crizotinib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!